Heart Failure. A Marvellous Story with More to Come. Prof Ken McDonald National Clinical Lead for Heart Failure
|
|
- Rolf Mills
- 6 years ago
- Views:
Transcription
1 Heart Failure A Marvellous Story with More to Come Prof Ken McDonald National Clinical Lead for Heart Failure
2 Advances in Heart Failure over Last 20 years Pharmacotherapy in HF-REF ADHF 50-15% Community 5 yr : 55% One mth /yr Device Rx in HF-REF Heart Failure Disease Management Programmes
3 Emerging new Strategies for Health Care in the Future Heart Failure Could the Cinderella of Medicine be the Guiding Light for Future Care
4 Emerging New Strategies for Heart Failure in the Future HF-PEF Prevention Heart Failure Primary-Secondary Care Interaction
5 Emerging New Strategies for Heart Failure in the Future HF-PEF Prevention Heart Failure Primary-Secondary Care Interaction
6 Heart Failure Numbers Now 20% Total At-Risk Population 1,000,000 Ireland 150,000,000 Europe 2030 Risk factor Control Diabetic Epidemic Lifestyle Improved Survival Prevalence to Increase by ~50%
7 The STOP-HF Story The First Personalised Approach to the Prevention of Heart Failure
8 At Risk Population ~1Million ~150 million Superior Risk Definition and Focused Use of Resources Critical to CV Management
9 Superiority of Natriuretic Peptide as Risk Indicator Hypertension, Diabetes, Obesity, Age, Cardiotoxins, etc Risk of Cardiovascular Damage Cardiovascular Damage Release of Natriuretic Peptide indicating Cardiovascular Damage Focus of Prevention Strategy
10 Natriuretic Peptides personalise Heart Failure Risk Wang et al, NEJM 2004
11 STOP-HF Hypothesis NP-driven screening and targeted collaborative care in the general at-risk population will decrease the prevalence of LVD and HF 39 collaborating primary care practices, intervention provided in a single referral center STOP-HF, JAMA, 2013
12 STOP-HF Intervention Routine PCP care NP-directed care In addition to routine PCP care Annual BNP in all Annual BNP not available to clinicians At least annual review by PCP Cardiology review only if requested by PCP If BNP >50pg/ml at any time Shared-care Cardiology review Echo-Doppler Other CV investigations CV nurse coaching Regular Cardiology follow-up STOP-HF, JAMA, 2013
13 Primary Endpoint HF and LVD OR 0.46 [0.27, 0.77], p= % 18.0% 16.0% 14.0% 12.0% 10.0% 8.0% 6.0% 4.0% 2.0% 0.0% OR 0.59 [0.38, 0.90], p=0.01 N=59 3.8% 2.8% 2.1% N=39 N=44 6.4% N=25 7.2% 3.0% 2.0% 4.6% 2.3% 5.1% 1.0% 1.9% Control Intervention Control Intervention Total All patients Population Any BNP > >= pg/ml LVDD LVSD HF STOP-HF, JAMA, 2013
14 Number of events per 1,000 patient years Endpoint MACE Event Rate 45 Event Rate OR 0.54 p=0.001 vs. Control Stroke/TIA PE/DVT MI Heart Failure Arrhythmia 0 Control Intervention N=71 (10.5%) N=51 (7.3%)
15 The PONTIAC Study Achieved Primary End-point: Hospitalisation or Death / Cardiac Effectiveness of RAAS / BB Titration JACC, 2013
16 STOP-HF and PONTIAC; Comparison of Pharmacotherapy at Study End Intervention Control PONTIAC BB STOP-HF BB PONTIAC RAAS STOP-HF RAAS
17 Cost Analysis of STOP-HF CONTROL Control (n=522) Mean (SD) INTERVENTION Intervention (n=533) Mean (SD) 6,238 per gain life year free of MACE CV Emergencies 1460 (4478) 795 (3010)** CV Electives 1471 (6702) 1311 (5314) Investigations/Tests 503 (599) 875 (951)** Non-CV Emergencies 1622 (4495) 1684 (4521) Non-CV Electives 2600 (5862) 2552 (5149) Medications 1776 (999) 1902 (1095) STOP Visits (460)** BNPs 61 (29) 71 (31) GP visits 197 (95) 232 (102)* Total 9689 (12353) 9774 (11049) Intention to treat 7495 (9446) 7614 (8698) The incremental cost per LVD/HF prevented was 2693 (sensitivity to 12926) and per MACE prevented 1139 (sensitivity to 5469) Ledwidge et al, Athens 2014
18 Event rate per 100 patient-years Hospitalisation & Death Across Spectrum * 12.4 * * * * * * * HF event Non-HF CV event Non-CV event Death Stage A Stage B Stage C
19 Services in Republic of Ireland Dublin South Wicklow Wexford STOP-HF
20 Services in Republic of Ireland Westmeath Offaly Laois STOP HF Midlands
21 Emerging New Strategies for Heart Failure in the Future HF-PEF Prevention Heart Failure Primary-Secondary Care Interaction
22 How Complex if Heart Failure Management? The Diagnostic Challenge The Therapeutic Challenge
23 Damn Difficult Diagnosis : Is it or Isn t it 78yrold male - GP referral-rapid access clinic DOE ( Class 11 )-commenced on low dose loop? Marginally better AF for years Previous normal Cors No lung history Exam AF-no volume overload ; BMI 30 ECG : AF nil else NP ( BNP) : 136pg/ml Echo Normal EF, Biatrial Enlargement, normal Valves, no increase in Pulmonary Pressures
24 How Complex if Heart Failure Management? The Diagnostic Challenge Using Echo properly Not just LVEF / Valve LA for PEF E /e Prime Understanding NP Two assays RCV 30% The Therapeutic Challenge
25 Confidence if Diagnosing HF-PEF: Cardiologists: 58% General Physicians: 43% General Practitioners: 7% Heart Failure Nurses: 6% 2015
26 How Complex if Heart Failure Management? The Diagnostic Challenge The Therapeutic Challenge HF-REF: Diuretic Nitrate ACEi / ARB/ AA/ ARNi Ivabradine Digoxin Inodilators Device Rx HF-PEF? Co-morbidity Symptom Differentiation Polypharmacy
27 Barriers Explaining Practice Gap in Ireland Waiting times for outpatient appointments Lack of access to echocardiography Inadequate access to Natriuretic Peptide testing Patients unable to attend outpatients Unsure of interpretation of tests Other Yes (%) 89.4% (n=222) 81.4% (n=226) 63.4% (n=227) 37.5% (n=224) 34.4 % (n=221) 3.1% (n=228) 68.8% of GPs in urban practices would refer over 50% of their patients for specialist opinion 50.6% of mixed urban-rural practices
28 Practice Gap in the UK 34% of patients with an existing clinical label of heart failure in general practice records had this diagnosis confirmed following echocardiography Hobbs FDR et al. Reliability of N-terminal pro-brain natriuretic peptide assay in diagnosis of heart failure: cohort study in representative and high risk community populations. BMJ 2002;324: Most patients are diagnosed on symptoms and signs alone, with only 32% having further investigations or referral. Hobbs FDR et al. European survey of primary care physician perceptions and practice in heart failure diagnosis and management (Euro-HF study). Eur Heart J 2000;21:
29 Practice Gap in Sweden
30 Practice Gap The Challenge Prompt diagnostics t Prompt specialist opinion Self care education Process of refreshing care to reflect advances, impact of evolving comorbidities Process of re-enforcing self care
31 Outpatients ED Admission
32 Many medical interactions don t require the patient!!! ehealth Keep the limited real slots for needed patient review Outpatients ED Admission
33
34
35 262 cases reviewed by VC May 2014 Oct 2015
36 82% do not require referral to out-patients
37
38 50,000 km saved in travel Elderly/Frail. Multiple comorbidities. Limited means to travel.
39 Emerging new Strategies for Health Care in the Future Heart Failure Focus on Prevention and Enhanced Communication between Primary and Secondary Care
Management of Heart Failure from diagnosis to the grave. Richard Lawrance Consultant Cardiologist - WMH
Management of Heart Failure from diagnosis to the grave Richard Lawrance Consultant Cardiologist - WMH Case Presentation 55y man Breathless Ex tolerance 100yds on flat, limited by SOB No chest pain Borderline
More informationHeart Failure Acute and Chronic
Heart Failure Acute and Chronic Cardiac Services in Wales Acute Heart Failure standards Chronic Heart Failure standards NWIS admissions/readmission data NHFA data 2016-17 Echo accessibility BNP availability
More informationChallenges and opportunities in heart failure treatment: Irish example
Challenges and opportunities in heart failure treatment: Irish example Joe Gallagher University College Dublin Ireland The Irish healthcare system Mixed public and private funding Primary healthcare is
More informationDECLARATION OF CONFLICT OF INTEREST
DECLARATION OF CONFLICT OF INTEREST Is there a mortality risk associated with aspirin use in heart failure? Results from a large community based cohort Margaret Bermingham, Mary-Kate Shanahan, Saki Miwa,
More informationNew NICE Heart Failure Guidelines What do they mean for primary and secondary care, and patients?
New NICE Heart Failure Guidelines 2018 - What do they mean for primary and secondary care, and patients? Prof Ahmet Fuat PhD FRCGP FRCP PG Dip (Cardiology) GP & GPSI Cardiology Darlington Professor of
More information8:30-10:30 WS #4: Cardiology :00-13:00 WS #11: Cardiology 101 (Repeated)
Professor Ralph Stewart Cardiologist Auckland City Hospital Green Lane Cardiovascular Research Unit Auckland Heart Group Fiona Stewart Cardiologist Green Lane Hospital National Women's Hospital Professor
More informationHeart Failure in 2012 with reference to NICE Guidance Dr Maurice Pye Consultant Cardiologist York District Hospital
Heart Failure in 2012 with reference to NICE Guidance 2010 Dr Maurice Pye Consultant Cardiologist York District Hospital A little over elaborate,do not include ECG or CXR If clinical suspicion is high
More information2017 CCS HF Guidelines Medical Therapy for HFrEF When What Order and How Much?
2017 CCS HF Guidelines Medical Therapy for HFrEF When What Order and How Much? Dr. Shelley Zieroth University of Manitoba @ShelleyZieroth @CanHFSociety Disclosures Consulting/Advisory Board: Amgen, Astra
More informationCongestive Heart Failure: Outpatient Management
The Chattanooga Heart Institute Cardiovascular Symposium Congestive Heart Failure: Outpatient Management E. Philip Lehman MD, MPP Disclosure No financial disclosures. Objectives Evidence-based therapy
More informationThe ACC Heart Failure Guidelines
The ACC Heart Failure Guidelines Fakhr Alayoubi, Msc,R Ph President of SCCP Cardiology Clinical Pharmacist Assistant Professor At King Saud University King Khalid University Hospital Riyadh-KSA 2017 ACC/AHA/HFSA
More informationNatriuretic Peptides The Cardiologists View. Christopher defilippi, MD University of Maryland Baltimore, MD, USA
Natriuretic Peptides The Cardiologists View Christopher defilippi, MD University of Maryland Baltimore, MD, USA Disclosures Research support: Alere, BG Medicine, Critical Diagnostics, Roche Diagnostics,
More information2017 ACC/AHA/HFSA HF guidelines. Advances in the Use of Biomarkers in Heart Failure Patients. Outline
Advances in the Use of Biomarkers in Heart Failure Patients Lori B. Daniels, MD, MAS, FACC, FAHA Professor of Medicine Director, Cardiovascular Intensive Care Unit Sulpizio Cardiovascular Center UC San
More informationHeart Failure 101 The Basic Principles of Diagnosis & Management
Heart Failure 101 The Basic Principles of Diagnosis & Management Bill Tran, MD Non Invasive Cardiologist February 24, 2018 What the eye does not see and the mind does not know, does not exist. DH Lawrence
More informationImproving Diagnostic, Prognostic & Therapeutic Biomarkers in Heart Disease. Professor Mark Richards Medicine, University of Otago, Christchurch
Improving Diagnostic, Prognostic & Therapeutic Biomarkers in Heart Disease Professor Mark Richards Medicine, University of Otago, Christchurch BNP / NT-ProBNP H 2 N 1 Pro-BNP Cardiomyocyte 76 77 108 COOH
More informationEnhancing the Quality of Heart Failure Care
Enhancing the Quality of Heart Failure Care 2 Enhancing the quality of Heart Failure care Kent Surrey Sussex Academic Health Science Network 3 Contents 2 Heart failure care in the UK: Case for change 3
More informationNCAP NATIONAL CARDIAC AUDIT PROGR AMME NATIONAL HEART FAILURE AUDIT 2016/17 SUMMARY REPORT
NCAP NATIONAL CARDIAC AUDIT PROGR AMME NATIONAL HEART FAILURE AUDIT 2016/17 SUMMARY REPORT CONTENTS PATIENTS ADMITTED WITH HEART FAILURE...4 Demographics... 4 Trends in Symptoms... 4 Causes and Comorbidities
More informationHeart Failure. GP Update Refresher 18 th January 2018
GP Update Refresher 18 th January 2018 Heart Failure Dr. Alexander Lyon Senior Lecturer and Consultant Cardiologist Clinical Lead in Cardio-Oncology Royal Brompton Hospital, London UK President of British
More informationHeart Failure with Reduced EF. Dino Recchia, MD, FACC, FHFSA
Heart Failure with Reduced EF Dino Recchia, MD, FACC, FHFSA Heart Failure HF is the end phenotype of almost all CV disorders Complex clinical syndrome resulting from any structural or functional impairment
More informationNICE Chronic Heart Failure Guidelines in Adults 2018
NICE Chronic Heart Failure Guidelines in Adults 2018 The Whys, Whats and Hows of the importance of effectively managing heart failure in Primary Care and the community. Foreword Dr Clare J Taylor, General
More informationNT-proBNP: Evidence-based application in primary care
NT-proBNP: Evidence-based application in primary care Associate Professor Rob Doughty The University of Auckland, Auckland City Hospital, Auckland Heart Group NT-proBNP: Evidence in Primary Care The problem
More informationHeart Failure A Disease for the Internist?
Heart Failure A Disease for the Internist? Dr Chris Davidson Sussex Cardiac Centre BRIGHTON UK Hot Topics in Heart Failure Drug treatments Valsartan / neprilysin inhib Investigations BNP and others Devices
More informationTherapeutic Targets and Interventions
Therapeutic Targets and Interventions Ali Valika, MD, FACC Advanced Heart Failure and Pulmonary Hypertension Advocate Medical Group Midwest Heart Foundation Disclosures: 1. Novartis: Speaker Honorarium
More informationDiagnosis and management of Chronic Heart Failure in 2018: What does NICE say? PCCS Meeting Issues and Answers Conference Nottingham
Diagnosis and management of Chronic Heart Failure in 2018: What does NICE say? PCCS Meeting Issues and Answers Conference Nottingham NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Chronic heart failure
More informationTreating HF Patients with ARNI s Why, When and How?
Treating HF Patients with ARNI s Why, When and How? 19 th Annual San Diego Heart Failure Symposium for Primary Care Physicians January 11-12, 2019 La Jolla, CA Barry Greenberg M.D. Distinguished Professor
More informationThe CCS Heart Failure Companion: Bridging Guidelines to your Practice
The CCS Heart Failure Companion: Bridging Guidelines to your Practice Looking for practical answers concerning optimal heart failure care? The CCS Heart Failure Guidelines Companion can help. The Canadian
More informationEnhancing the Quality of Heart Failure Care
Enhancing the Quality of Heart Failure Care 2 Enhancing the quality of Heart Failure care Contents 2 Heart failure care in the UK: Case for change Heart failure in the UK: Case for change Heart failure
More informationNatriuretic Peptide Guided Therapy for Heart Failure
Natriuretic Peptide Guided Therapy for Heart Failure Michael Felker, MD, MHS Associate Professor of Medicine Director of Heart Failure Research Duke Clinical Research Institute Disclosures Research Grants
More informationThe Failing Heart in Primary Care
The Failing Heart in Primary Care Hamid Ikram How fares the Heart Failure Epidemic? 4357 patients, 57% women, mean age 74 years HFSA 2010 Practice Guideline (3.1) Heart Failure Prevention A careful and
More informationHeart Failure Management. Waleed AlHabeeb, MD, MHA Assistant Professor of Medicine Consultant Heart Failure Cardiologist
Heart Failure Management Waleed AlHabeeb, MD, MHA Assistant Professor of Medicine Consultant Heart Failure Cardiologist Heart failure prevalence is expected to continue to increase¹ 21 MILLION ADULTS WORLDWIDE
More informationHFpEF, Mito or Realidad?
HFpEF, Mito or Realidad? Ileana L. Piña, MD, MPH Professor of Medicine and Epidemiology/Population Health Associate Chief for Academic Affairs -- Cardiology Montefiore-Einstein Medical Center Bronx, NY
More informationA Global perspective on Heart Failure: What needs to change? Martin R Cowie London, United Kingdom
A Global perspective on Heart Failure: What needs to change? Martin R Cowie London, United Kingdom Global perspective on heart failure: what needs to change? Martin R Cowie Professor of Cardiology National
More informationHeart Failure Medical and Surgical Treatment
Heart Failure Medical and Surgical Treatment Daniel S. Yip, M.D. Medical Director, Heart Failure and Transplantation Mayo Clinic Second Annual Lakeland Regional Health Cardiovascular Symposium February
More information21/06/2018. MEASURING PERFORMANCE (AUDIT AND QUALITY IMPROVEMENT) Towards Reducing Inequity. What should we be measuring?
MEASURING PERFORMANCE (AUDIT AND QUALITY IMPROVEMENT) Towards Reducing Inequity Dr Raewyn Fisher Cardiologist Director of Waikato Integrated Heart Failure Service What should we be measuring? At risk,
More informationOptimal blockade of the Renin- Angiotensin-Aldosterone. in chronic heart failure
Optimal blockade of the Renin- Angiotensin-Aldosterone Aldosterone- (RAA)-System in chronic heart failure Jan Östergren Department of Medicine Karolinska University Hospital Stockholm, Sweden Key Issues
More informationESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure
Patients t with acute heart failure frequently develop chronic heart failure Patients with chronic heart failure frequently decompensate acutely ESC Guidelines for the Diagnosis and A clinical response
More informationUPDATES IN MANAGEMENT OF HF
UPDATES IN MANAGEMENT OF HF Jennifer R Brown MD, MS Heart Failure Specialist Medstar Cardiology Associates DC ACP Meeting Fall 2017 Disclosures: speaker bureau for novartis speaker bureau for actelion
More informationBurden of Mitral Regurgitation (MR) in the US Why is This Important?
Secondary (Functional) Mitral Regurgitation as a Target for Heart Failure Therapy William T. Abraham, MD, FACP, FACC, FAHA, FESC, FRCP Professor of Medicine, Physiology, and Cell Biology Chair of Excellence
More informationCommunity Cardiology Service - Reinventing Care
Cardiology Community Cardiology Service - Reinventing Care Dr Dilsher Singh Clinical Cardiology Lead Connected care Partnership Background Evidence of Need Cardiology accounts for high volumes of OP activity
More informationHeart Failure Update. Chim Lang
Heart Failure Update Chim Lang Heart Failure Patient s Journey Acute Treat and stabilize Initiate monitoring Plan interventions Chronic Optimize drug and device therapy Manage Co-morbidities Subacute
More informationHeart Failure. Disclosures. Objectives: 8/28/2017. This is not a virus. It doesn t go away. none
Heart Failure This is not a virus. It doesn t go away Shelley Wojtaszczyk, FNP-C, CHFN Heart Failure Program Coordinator Mercy Hospital of Buffalo none Disclosures Objectives: Defining and identifying
More informationUpdates in Congestive Heart Failure
Updates in Congestive Heart Failure GREGORY YOST, DO JOHNSTOWN CARDIOVASCULAR ASSOCIATES 1/28/2018 Disclosures Edwards speaker on Sapien3 valves (TAVR) Stages A-D and NYHA Classes I-IV Stage A: High risk
More informationHFpEF. April 26, 2018
HFpEF April 26, 2018 (J Am Coll Cardiol 2017;70:2476 86) HFpEF 50% or more (40-71%) of patients with CHF have preserved LV systolic function. HFpEF is an increasingly frequent hospital discharge. Outcomes
More informationBiomarker-guided HF: What have we learned (so far)?
Biomarker-guided HF: What have we learned (so far)? James L. Januzzi, Jr, MD, FACC, FESC Associate Professor of Medicine Harvard Medical School Director, Cardiac ICU Massachusetts General Hospital DECLARATION
More informationLearning Objectives. Predicting and Preventing Cardiovascular Disease. ACC/AHA Cholesterol Guidelines Key differences vs ATP III
Presenter Disclosure Information 10:30 11:15am Predicting and Preventing Cardiovascular Disease: Can we put the Cardiologist out of business? The following relationships exist related to this presentation:
More informationA New Approach to Addressing the Heart Failure Challenge in Primary Care within the Western Locality of NEW DEVON CCG
A New Approach to Addressing the Heart Failure Challenge in Primary Care within the Western Locality of NEW DEVON CCG Dr Rosie Heath GP Principal Church view medical centre and GPwSI Western locality Cardiology
More informationHeart Failure with Preserved EF (HFPEF) Epidemiology and management
Heart Failure with Preserved EF (HFPEF) Epidemiology and management Karl Swedberg Senior Professor of Medicine Sahlgrenska Academy University of Gothenburg Gothenburg, Sweden e-mail: karl.swedberg@gu.se
More informationCardiology. Presented by: Dr Paul Bethell GP Lead for Planned Care
Cardiology Presented by: Dr Paul Bethell GP Lead for Planned Care 16 th April 2015 Integrated Cardiology Service for Ipswich and East Suffolk CCG IHT 6 consultants - all with specialist areas PCI CoW rapid
More informationDISCLAIMER: ECHO Nevada emphasizes patient privacy and asks participants to not share ANY Protected Health Information during ECHO clinics.
DISCLAIMER: Video will be taken at this clinic and potentially used in Project ECHO promotional materials. By attending this clinic, you consent to have your photo taken and allow Project ECHO to use this
More informationΜαρία Μπόνου Διευθύντρια ΕΣΥ, ΓΝΑ Λαϊκό
Μαρία Μπόνου Διευθύντρια ΕΣΥ, ΓΝΑ Λαϊκό Diastolic HF DD: Diastolic Dysfunction DHF: Diastolic HF HFpEF: HF with preserved EF DD Pathophysiologic condition: impaired relaxation, LV compliance, LV filling
More informationA patient with decompensated HF
A patient with decompensated HF Professor Michel KOMAJDA University Pierre & Marie Curie Pitie Salpetriere Hospital Department of Cardiology Paris (France) Declaration Of Interest 2010 Speaker : Servier,
More informationHow might biomarkers and other strategies help establish adequacy of care?
How might biomarkers and other strategies help establish adequacy of care? James L. Januzzi, Jr, MD, FACC, FESC Hutter Family Professor of Medicine, Harvard Medical School Cardiology Division, Massachusetts
More informationHeart Failure Clinician Guide JANUARY 2016
Kaiser Permanente National CLINICAL PRACTICE GUIDELINES Heart Failure Clinician Guide JANUARY 2016 Introduction This evidence-based guideline summary is based on the 2016 National Heart Failure Guideline.
More informationFrom PARADIGM-HF to Clinical Practice. Waleed AlHabeeb, MD, MHA Associate Professor of Medicine President of the Saudi Heart Failure Group
From PARADIGM-HF to Clinical Practice Waleed AlHabeeb, MD, MHA Associate Professor of Medicine President of the Saudi Heart Failure Group PARADIGM-HF: Inclusion Criteria Chronic HF NYHA FC II IV with LVEF
More informationGerasimos Filippatos MD, FESC, FCCP, FACC
Gerasimos Filippatos MD, FESC, FCCP, FACC Head of HF Unit at Athens University Hospital, Greece President (2014-2016) of the HF Association of the European Society of Cardiology (ESC) Served as Chair of
More informationHF-Preserved Ejection Fraction
HF-Preserved Ejection Fraction Justin A. Ezekowitz, MBBCh MSc FRCPC FACC FESC FAHA Associate Professor, University of Alberta Co-Director, Canadian VIGOUR Centre Cardiologist, Mazankowski Alberta Heart
More informationEvaluation of a diagnostic pathway in heart failure in primary care, using electrocardiography and brain natriuretic peptide guided echocardiography
Evaluation of a diagnostic pathway in heart failure in primary care, using electrocardiography and brain natriuretic peptide guided echocardiography Rebecka Karlsson Pardeep Jhund 1 Material and methods
More informationChecklist for Treating Heart Failure. Alan M. Kaneshige MD, FACC, FASE Oklahoma Heart Institute
Checklist for Treating Heart Failure Alan M. Kaneshige MD, FACC, FASE Oklahoma Heart Institute Novartis Disclosure Heart Failure (HF) a complex clinical syndrome that arises secondary to abnormalities
More informationChronic heart failure: management of chronic heart failure in adults in primary and secondary care (partial update)
Chronic heart failure: management of chronic heart failure in adults in primary and secondary care (partial update) NICE guideline Apendix C The algorithms Draft for consultation, January 2010 Chronic
More information6/29/2017. Role of Biomarkers in the Management of Heart Failure Patients. What s New in Biomarkers for HF Patients?
What s New in Biomarkers for HF Patients? Role of Biomarkers in the Management of Heart Failure Patients Lori B. Daniels, MD, MAS, FACC Professor of Medicine Director, Cardiovascular Intensive Care Unit
More information1000 Lives Key Components of Reliable, Evidence-Based Chronic Heart Failure Care how do we compare?
1000 Lives Key Components of Reliable, Evidence-Based Chronic Heart Failure Care how do we compare? Dr Nerys Davies, GPST Ms B. Davies, Specialist Nurse (Heart Failure) Dr J. Taylor, Consultant Cardiologist
More informationHeart Failure Guidelines For your Daily Practice
Heart Failure Guidelines For your Daily Practice Juan M. Aranda, Jr., MD, FACC, FHFSA Professor of Medicine Director of Heart Failure and Cardiac Transplantation University of Florida College of Medicine
More informationREGIONAL DIFFERENCES IN HF SERVICE DEMAND AND DELIVERY
REGIONAL DIFFERENCES IN HF SERVICE DEMAND AND DELIVERY Raewyn Fisher, Waikato Hospital On behalf of Midland Cardiac Network (With thanks to Population Health data analysts) Cardiac Network Plans (Midland)
More informationThe Therapeutic Potential of Novel Approaches to RAAS. Professor of Medicine University of California, San Diego
The Therapeutic Potential of Novel Approaches to RAAS Inhibition in Heart Failure Barry Greenberg, M.D. Professor of Medicine University of California, San Diego Chain of Events Leading to End-Stage Heart
More informationRole of Biomarkers for the Prevention, Assessment, and Management of Heart Failure: A Scientific Statement From the American Heart Association
Role of Biomarkers for the Prevention, Assessment, and Management of Heart Failure: A Scientific Statement From the American Heart Association We combed through both guidelines and summarized 3 recommendations
More informationHeFSSA Practitioners Program 2017 Theme The Patient Journey: Feel Good and Live Long. Case Study 2
HeFSSA Practitioners Program 2017 Theme The Patient Journey: Feel Good and Live Long Case Study 2 HEART FAILURE WITH MID-RANGE EJECTION FRACTION TREATMENT OPTIONS CLINICAL CASE MEDICAL HISTORY 59-year-old
More informationPercutaneous Mitral Valve Repair: What Can We Treat and What Should We Treat
Percutaneous Mitral Valve Repair: What Can We Treat and What Should We Treat Innovative Procedures, Devices & State of the Art Care for Arrhythmias, Heart Failure & Structural Heart Disease October 8-10,
More informationHeart Failure. Optimising treatment and balancing co-morbidity in the community. Andrew Ludman Cardiologist
Heart Failure Optimising treatment and balancing co-morbidity in the community Andrew Ludman Cardiologist What is heart failure? A structural cardiac abnormality leading to failure of the heart to provide
More informationHeart Failure (HF) - Primary Care Flow Charts. Pre diagnosis Symptoms or signs suggestive of HF
Heart Failure (HF) - Primary Care Flow Charts Pre diagnosis Symptoms or signs suggestive of HF 12 lead ECG Normal examination and 12 lead ECG HF highly unlikely Abnormal 12 lead ECG HF Possible Arrange
More informationHeart Failure (HF) - Primary Care Flow Charts. Symptoms or signs suggestive of HF. Pre diagnosis. Refer to the Heart Failure Clinic at VHK for
Heart Failure (HF) - Primary Care Flow Charts Pre diagnosis Symptoms or signs suggestive of HF 12 lead ECG Normal examination and 12 lead ECG HF highly unlikely Abnormal 12 lead ECG HF Possible Arrange
More informationPRESS RELEASE. New NICE guidance will improve diagnosis and treatment of chronic heart failure
Tel: 0845 003 7782 www.nice.org.uk Ref: 2010/118 ISSUED: WEDNESDAY, 25 AUGUST 2010 PRESS RELEASE New NICE guidance will improve diagnosis and treatment of chronic heart failure The National Institute for
More informationGOVERNING BODY REPORT
GOVERNING BODY REPORT DATE OF MEETING: 20th September 2012 TITLE OF REPORT: KEY MESSAGES: NHS West Cheshire Clinical Commissioning Group has identified heart disease as one of its six strategic clinical
More informationPravin Manga Division of Cardiology Department of Medicine University of Witwatersrand
Pravin Manga Division of Cardiology Department of Medicine University of Witwatersrand Overview Definition Epidemiology Biomarkers Treatment Clinical Heart Failure: Syndrome in which patients have typical
More informationheart failure John McMurray University of Glasgow.
A to Z of RAAS blockade in heart failure John McMurray BHF Cardiovascular Research Centre University of Glasgow. RAAS inhibition in CHF ACE inhibition in patients with low LVEF CHF CONSENSUS Enalapril
More informationPost MI LVSD Teach and Treat
Post MI LVSD Teach and Treat Scottish Heart Failure Nurse Forum GJNH, Sept 2017 Dr Clare Murphy Consultant Cardiologist Clinical Lead, National Heart Failure Hub Background to Post MI LVSD Teach and Treat
More informationSGK 2016 Session: Postgraduate Course in Heart Failure Lausanne, 15. June 2016 Heart Failure Guidelines 2016
SGK 2016 Session: Postgraduate Course in Heart Failure Lausanne, 15. June 2016 Heart Failure Guidelines 2016 Matthias Nägele, MD University Hospital Zurich Disclosures I have nothing to disclose. The new
More informationMean INTERHEART Risk Score (IHRS) Yusuf et al NEJM 2014
Mean INTERHEART Risk Score (IHRS) Yusuf et al NEJM 2014 CVD Event Rates Major CVD = death from CV causes, stroke, MI and HF Non major CVD = all other CVD events that led to hospitalization Yusuf et al
More informationMedical management of LV aneurysm and subsequent cardiac remodeling: is it enough? J. Parissis Attikon University Hospital Athens, Greece
Medical management of LV aneurysm and subsequent cardiac remodeling: is it enough? J. Parissis Attikon University Hospital Athens, Greece Disclosures Grants: ALARM investigator received research grants
More informationHEART FAILURE IN WOMEN. Marian Limacher, MD Division of Cardiovascular Medicine University of Florida
HEART FAILURE IN WOMEN Marian Limacher, MD Division of Cardiovascular Medicine University of Florida Outline Epidemiology Clinical Overview Why HF is such a challenge State of the Field Heart Failure Adjudication
More informationAdvanced Heart Failure Management. Dr Andrew Hannah Consultant Cardiologist Aberdeen Royal Infirmary
Advanced Heart Failure Management Dr Andrew Hannah Consultant Cardiologist Aberdeen Royal Infirmary Grading of heart failure Mr WY age 73 3/12 dyspnoea, fatigue and some ankle oedema PMH: hypertension
More informationBNP as a Predictor of Cardiovascular Disease and All Cause Mortality. Dr. Thierry Le Jemtel
BNP as a Predictor of Cardiovascular Disease and All Cause Mortality Dr. Thierry Le Jemtel Outline Role of BNP and probnp as relevant biomarkers in cardiac conditions Role of BNP and probnp as relevant
More informationHeart Failure Challenges and Unmet needs
Heart Failure Challenges and Unmet needs. Angelo Auricchio, MD FESC Director, Cardiac Electrophysiology Programme, Fondazione Cardiocentro Ticino, Lugano, Switzerland Professor of Cardiology, University
More informationCLINICAL PRACTICE GUIDELINE
CLINICAL PRACTICE GUIDELINE Procedure: Congestive Heart Failure Guideline Review Cycle: Biennial Reviewed By: Amish Purohit, MD, MHA, CPE, FACHE Review Date: November 2014 Committee Approval Date: 11/12/2014
More informationNew in Heart Failure SGK autumn session 2012
New in Heart Failure SGK autumn session 2012 Roger Hullin Cardiology Department of Internal Medicine Centre Universitaire Hospitaler Vaudois University of Lausanne ESC Heart Failure Guidelines 2012 Classes
More informationConflict of interest statement
Risk of stroke, systemic embolism or death according to heart failure and left ventricular function status in patients with atrial fibrillation: results of the ARISTOTLE trial J.J.V. McMurray 1, B. Lewis
More informationAdvanced Care for Decompensated Heart Failure
Advanced Care for Decompensated Heart Failure Sara Kalantari MD Assistant Professor of Medicine, University of Chicago Advanced Heart Failure, Mechanical Circulatory Support and Cardiac Transplantation
More informationDisclosures. Overview. Goal statement. Advances in Chronic Heart Failure Management 5/22/17
Disclosures Advances in Chronic Heart Failure Management I have nothing to disclose Van N Selby, MD UCSF Advanced Heart Failure Program May 22, 2017 Goal statement To review recently-approved therapies
More informationBeta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes
Beta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes Seung-Jae Joo and other KAMIR-NIH investigators Department of Cardiology, Jeju National
More informationDrugs acting on the reninangiotensin-aldosterone
Drugs acting on the reninangiotensin-aldosterone system John McMurray Eugene Braunwald Scholar in Cardiovascular Diseases, Brigham and Women s Hospital, Boston & Visiting Professor, Harvard Medical School
More informationHeart Failure from a GP perspective
Heart Failure from a GP perspective Jane Gilmour, Alison Wright Clinical Nurse Specialists for Heart Failure The Heart failure Team Dr Ganesan Kumar- Consultant Cardiologist Dr D Maras- Staff Grade Cardiology
More informationNew PINNACLE Measures The below measures for PINNACLE will be added as new measures to the outcomes reporting starting with Version 2.0.
New PINNACLE Measures The below measures for PINNACLE will be added as new measures to the outcomes reporting starting with Version 2.0. Measure Steward Measure Name Measure Description Rationale for Adding
More informationDr Dinna Soon. Consultant Cardiologist, Department of Cardiology. GP symposium 2 April 2016
Dr Dinna Soon Consultant Cardiologist, Department of Cardiology GP symposium 2 April 2016 Case presentation 76 years old male, chronic smoker, hypertension, previous MI 3/7 SOB and chest tightness BP
More informationRAAS blocker + B Blocker Troubleshooting
RAAS blocker + B Blocker Troubleshooting Heart Failure ECHO Clinic Virtual Heart Failure Consultation and Education Prof Ken McDonald & Dr. Patricia Campbell 13 th March 2017 HF activates 3 neurohormonal
More informationAll Roads Lead to HF. Presenter Disclosure Information. After a Decade of (Almost) Nothing Multiple New Therapies for Heart Failure CAD.
After a Decade of (Almost) Nothing Multiple New Therapies for Heart Failure Larry A. Allen, MD, MHS Director for Advanced Heart Failure October 18, 2016 Presenter Disclosure Information I will not discuss
More informationDisclosures. Advances in Chronic Heart Failure Management 6/12/2017. Van N Selby, MD UCSF Advanced Heart Failure Program June 19, 2017
Advances in Chronic Heart Failure Management Van N Selby, MD UCSF Advanced Heart Failure Program June 19, 2017 I have nothing to disclose Disclosures 1 Goal statement To review recently-approved therapies
More informationHeart Failure Clinician Guide JANUARY 2018
Kaiser Permanente National CLINICAL PRACTICE GUIDELINES Heart Failure Clinician Guide JANUARY 2018 Introduction This evidence-based guideline summary is based on the 2018 National Heart Failure Guideline.
More informationEfficacy of beta-blockers in heart failure patients with atrial fibrillation: An individual patient data meta-analysis
Efficacy of beta-blockers in heart failure patients with atrial fibrillation: An individual patient data meta-analysis Dipak Kotecha, MD PhD on behalf of the Selection of slides presented at the European
More informationHeart Failure. Jay Shavadia
Heart Failure Jay Shavadia Definition Clinical syndrome characterized by: Symptoms: breathlessness at rest or on exercise, fatigue, tiredness or ankle swelling AND Signs: tachycardia, tachypnea, pulmonary
More informationHeart Failure Dr Eric Klug Sunninghill, Sunward Park, CM Johannesburg Academic Hospital
Heart Failure 2012 Dr Eric Klug Sunninghill, Sunward Park, CM Johannesburg Academic Hospital PRELOAD COWS Reduction in milk production INOTROPY & HEART RATE AFTERLOAD DISTRIBUTION NETWORK THE CLASSIC APPROACH
More informationTHE PROPER APPROACH TO DIAGNOSING HEART FAILURE WITH PRESERVED EJECTION FRACTION
THE PROPER APPROACH TO DIAGNOSING HEART FAILURE WITH PRESERVED EJECTION FRACTION James C. Fang, MD, FACC Professor and Chief Cardiovascular Division University of Utah School of Medicine Disclosures Data
More informationREVIEW OF HEART FAILURE INDICATORS IN CHESHIRE AND MERSEYSIDE
REVIEW OF HEART FAILURE INDICATORS IN CHESHIRE AND MERSEYSIDE DEVELOPING BASELINES TO MEASURE IMPROVEMENTS OCTOBER 2012 SAM JAMES SAM.JAMES@NORTHWEST.NHS.UK RUTH GRAINGER RUTH.GRAINGER@CISSU.NHS.UK ANNE
More information